Inhalation Sciences to present FDA-funded DissolvIt evaluation results at respiratory drug development conferences

PUBT · 2d ago
Inhalation Sciences to present FDA-funded DissolvIt evaluation results at respiratory drug development conferences
  • Inhalation Sciences will present results from an FDA-funded evaluation of DissolvIt at three conferences in August–October 2026.
  • Poster presentation scheduled for the Rapid Response Partnership Vehicle General Membership Meeting in Arlington, Maryland, Aug. 26–27, 2026.
  • Poster presentation planned for the Inhaled & Nasal Biologics I DNA Forum in Cambridge, UK, Sept. 24–25, 2026.
  • Podium presentation slated for the MVIC Symposium in Lund, Sweden, Oct. 21–22, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhalation Sciences Sweden AB published the original content used to generate this news brief via Cision (Ref. ID: 202608200230BITN____UKPR__EN_20260819-BIT-9742-0) on August 20, 2026, and is solely responsible for the information contained therein.